Riskpilot← Back to searchSign inGet full accessDiffracTox AB
ABActiveOrg 5592005754Sergeantgränd 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2025
SEK 147K
+268% vs 2024
EBITDA margin
57.4%
+392% vs 2024
Equity ratio
72.4%
Financial strength
Net profit 2025
SEK 179K
-60% vs 2024
| Revenue | SEK 147K | +268% |
| EBITDA | SEK 84K | +392% |
| Net profit | SEK 179K | -60% |
| Total assets | SEK 3,2M | -4% |
| Equity | SEK 2,3M | -1% |
| Employees | 0 | — |
Legal name
DiffracTox AB
Org number
5592005754
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 mars 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall driva konsultverksamhet inom biomedicin och läkemedelsutveckling, samt äga, förvalta, utveckla och exploatera patent, upplåta licensrättigheter, äga och förvalta värdepapper ävensom idka annan därmed förenlig verksamhet.
Address
Sergeantgränd 16
Email
stenmark@dbb.su.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 1 609 | 4 191 | 1 610 | 0 | 0 | 40 | 147 |
| Staff expenses | — | — | — | −0 | — | — | −14 |
| EBITDA | 1 320 | 3 084 | 1 125 | −62 | −61 | −29 | 84 |
| Depreciation & amort. | −0 | −0 | −0 | −9 | −58 | −65 | −65 |
| EBIT | 1 320 | 3 084 | 1 125 | −72 | −120 | −94 | 19 |
| Net financials | — | −2 | — | −370 | −206 | 479 | 50 |
| Profit before tax | 991 | 2 312 | 843 | −232 | −205 | 455 | 219 |
| Tax | −212 | −495 | −175 | −31 | −6 | −4 | −40 |
| Net profit | 779 | 1 817 | 668 | −264 | −211 | 451 | 179 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 1 854 | 5 164 | 4 822 | 3 703 | 3 166 | 3 348 | 3 198 |
| Equity | 829 | 2 469 | 2 954 | 2 503 | 2 096 | 2 348 | 2 317 |
| Long-term debt | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 696 | 1 596 | 487 | 27 | 18 | 19 | 49 |
| Total debt | 696 | 1 596 | 487 | 27 | 18 | 19 | 49 |
EBITDA margin
57.4%
This company
15.8%
Market median
+263% vs market
20192025
Equity ratio
72.4%
This company
38.2%
Market median
+90% vs market
20192025
Return on equity
7.7%
This company
18.4%
Market median
-58% vs market
20192025
Net profit margin
121.8%
This company
8.1%
Market median
+1404% vs market
20192025
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20192025
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20192025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-03-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DiffracTox AB 
ToxoTech ABBoard members of DiffracTox AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pål Erik Gustav Stenmark | Chief Executive Officer | 0 companies |
| Lars Erik Gustav Stenmark | Deputy Board Member | 0 companies |